Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Cenexi is committed to working closely with the ANSM to address the observations
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Subscribe To Our Newsletter & Stay Updated
